Centre de coopération internationale en recherche agronomique pour le développement

CSL Seqirus Presents Real-World Evidence at ESWI Demonstrating the Impact of Influenza Vaccination Campaigns to Help Protect People and Healthcare Systems

Retrieved on: 
Tuesday, September 19, 2023
European Scientific Cooperative on Phytotherapy, Centre de coopération internationale en recherche agronomique pour le développement, Public, RCT, Season, ASX, CSL, Research, Science, Influenza, Patient, Risk, Randomized controlled trial, Disease, RWE, Mortality, Vaccine, Conference, Pneumonia

SUMMIT, N.J., Sept. 18, 2023 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX:CSL), today shared new real-world evidence (RWE) studies conducted in the United States, demonstrating the value of influenza vaccination in protecting public health.

Key Points: 
  • SUMMIT, N.J., Sept. 18, 2023 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX:CSL), today shared new real-world evidence (RWE) studies conducted in the United States, demonstrating the value of influenza vaccination in protecting public health.
  • These data are being presented at oral and poster sessions at the European Scientific Working Group on Influenza (ESWI) Conference taking place in Valencia, from September 17-20, 2023.
  • "At CSL Seqirus, we are committed to advancing the science of influenza prevention, and these studies show the benefits of innovative vaccine technologies, including cell-based and adjuvanted influenza vaccine technology, on reducing the burden of flu."
  • RWE is a complement to randomized controlled trial (RCT) research, assessing influenza vaccine effectiveness on a continual basis and providing an ever-growing data set on real-world outcomes.

Fondazione Ernesto Illy and illycaffè Inaugurate the 12th Academic Year of the Ernesto Illy Master's Degree in Coffee Science and Economics

Retrieved on: 
Thursday, January 12, 2023
Economics, University of Udine, Illy, International Coffee Organization, Woman, Engineering, KEDGE Business School, International School for Advanced Studies, University of Copenhagen, Drexel University, University, Student, Culture, Environment, Master, Restaurant, Art, Beauty, International school, Centre de coopération internationale en recherche agronomique pour le développement, Science, Collection, University of Trieste, SISSA, B Corporation (certification), Ernesto Illy, Coffee, Management

TRIESTE, Italy, Jan. 12, 2023 /PRNewswire/ -- The 12th Academic Year of the Ernesto Illy First-level Inter-University Master's Degree in Coffee Science and Economics was inaugurated.

Key Points: 
  • TRIESTE, Italy, Jan. 12, 2023 /PRNewswire/ -- The 12th Academic Year of the Ernesto Illy First-level Inter-University Master's Degree in Coffee Science and Economics was inaugurated.
  • The Ernesto Illy Master's Degree in Coffee Science and Economics, the only one of its kind in the world, confirms Trieste's standing a global hub of coffee culture.
  • By the end of the programme, 249 people from 25 different countries will have earned a Master's Degree in Coffee Science and Economics.
  • Since 2016, with the "Ernesto Illy International Coffee Award", the company has celebrated coffee growers all over the world that, according to illy, have produced the best sustainable coffee.

Seqirus Presents New Real-World Evidence Supporting Effectiveness of Differentiated Seasonal Influenza Vaccine Technologies at ISIRV-WHO Virtual Conference 2021

Retrieved on: 
Tuesday, October 19, 2021
ASX, Cohort study, Immune system, Allergy, WHO, Influenza, CDC, Death, MD, RWE, COVID-19, RVE, Pharmacy, Antibody, Centre de coopération internationale en recherche agronomique pour le développement, Guillain–Barré syndrome, Doctor of Philosophy, TNT, Ageing, Disease, Haemophilia, Muscle weakness, International Society, Vaccine, Selection bias, CSL Behring, Vaccination, R, Event-driven architecture, Patient, Conference, Neve Ativ, CSL, Adult, Population, Immunodeficiency, Degenerative disease, Health, Hospital, Health insurance

SUMMIT, N.J., Oct. 19, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting the effectiveness of its cell-based and adjuvanted seasonal influenza vaccines.

Key Points: 
  • SUMMIT, N.J., Oct. 19, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting the effectiveness of its cell-based and adjuvanted seasonal influenza vaccines.
  • "These retrospective studies, which include over 10 million vaccinated U.S. individuals, build on existing RWE in evaluating the effectiveness of influenza vaccines in real-world settings.
  • "These data support that our vaccines can help reduce IRMEs and minimize the burden of influenza, among children and older populations."
  • As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.